FR19C1062I1 - - Google Patents
Info
- Publication number
- FR19C1062I1 FR19C1062I1 FR19C1062C FR19C1062I1 FR 19C1062 I1 FR19C1062 I1 FR 19C1062I1 FR 19C1062 C FR19C1062 C FR 19C1062C FR 19C1062 I1 FR19C1062 I1 FR 19C1062I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607485P | 2012-03-06 | 2012-03-06 | |
| US201361759307P | 2013-01-31 | 2013-01-31 | |
| PCT/IB2013/051391 WO2013132376A1 (en) | 2012-03-06 | 2013-02-20 | Macrocyclic derivatives for the treatment of proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR19C1062I1 true FR19C1062I1 (en) | 2019-11-22 |
| FR19C1062I2 FR19C1062I2 (en) | 2020-09-04 |
Family
ID=48142828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR19C1062C Active FR19C1062I2 (en) | 2012-03-06 | 2019-10-23 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
Country Status (45)
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014212509B2 (en) | 2013-01-31 | 2018-05-10 | Vertex Pharmaceuticals Incorporated | Pyridone amides as modulators of sodium channels |
| US9637500B2 (en) | 2013-06-28 | 2017-05-02 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| CN104513253A (en) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | Macrocyclic compounds for the treatment of proliferative diseases |
| US9163042B2 (en) | 2013-12-13 | 2015-10-20 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| PL3097107T3 (en) * | 2014-01-24 | 2020-01-31 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| CN103772272A (en) * | 2014-03-04 | 2014-05-07 | 定陶县友帮化工有限公司 | Synthetic method of 2-BOC-amido-3-hydroxy-5-bromopyridine |
| US10159663B2 (en) * | 2014-08-20 | 2018-12-25 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| CN107108527B (en) | 2014-10-13 | 2022-08-02 | 阿特林制药有限责任公司 | Ataxia telangiectasia and Rad3-related (ATR) protein kinase inhibitors |
| US10085979B2 (en) | 2014-12-02 | 2018-10-02 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
| BR112017013982A2 (en) * | 2015-01-16 | 2018-01-02 | Chugai Seiyaku Kabushiki Kaisha | combination drug |
| EP3317285B1 (en) * | 2015-07-02 | 2021-01-27 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| RS65593B1 (en) | 2015-07-06 | 2024-06-28 | Turning Point Therapeutics Inc | Diaryl macrocycle polymorph |
| PL3733187T3 (en) | 2015-07-21 | 2025-01-07 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
| FI3798222T3 (en) | 2015-07-31 | 2023-11-28 | Pfizer | Crystalline form of lorlatinib free base |
| CA3000386A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| JP7061068B2 (en) | 2015-12-18 | 2022-04-27 | イグナイタ インコーポレイテッド | Combination drug for cancer treatment |
| WO2017148325A1 (en) | 2016-03-03 | 2017-09-08 | 深圳市塔吉瑞生物医药有限公司 | Macrocycle and composition comprising thereof |
| CN105732355A (en) * | 2016-04-07 | 2016-07-06 | 戊言医药科技（上海）有限公司 | Preparation method of 1-(5-fluoro-2-iodophenyl)ethanone |
| CN105646355A (en) * | 2016-04-07 | 2016-06-08 | 戊言医药科技（上海）有限公司 | Preparation method of 3-(hydroxymethyl)-1-methyl-pyrazole-5-formonitrile |
| ES2819676T3 (en) * | 2016-04-08 | 2021-04-19 | Pfizer | Crystalline forms of lorlatinib maleate |
| US10301324B2 (en) | 2016-04-12 | 2019-05-28 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use |
| CN105801603B (en) * | 2016-04-13 | 2018-10-02 | 成都倍特药业有限公司 | A kind of ALK inhibitor and preparation method thereof with macrocyclic structure |
| CA3031100A1 (en) | 2016-07-28 | 2018-02-01 | Tp Therapeutics, Inc. | Macrocycle kinase inhibitors |
| EP3548484B1 (en) * | 2016-12-02 | 2025-04-30 | F. Hoffmann-La Roche AG | Bicyclic amide compounds and methods of use thereof |
| TWI808958B (en) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
| WO2018137679A1 (en) * | 2017-01-25 | 2018-08-02 | Teligene Ltd | Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile |
| KR102714561B1 (en) | 2017-05-16 | 2024-10-10 | 버텍스 파마슈티칼스 인코포레이티드 | Deuterated pyridone amides and their prodrugs as modulators of sodium channels |
| KR20200020911A (en) | 2017-06-30 | 2020-02-26 | 바이엘 애니멀 헬스 게엠베하 | New Azaquinoline Derivatives |
| KR102718538B1 (en) | 2017-07-19 | 2024-10-21 | 이그니타, 인코포레이티드 | Pharmaceutical composition comprising entrectinib |
| PL3658148T3 (en) | 2017-07-28 | 2024-10-07 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
| DK3694863T3 (en) | 2017-10-10 | 2023-07-03 | Pfizer | Crystalline form of free base hydrate of lorlatinib |
| CN111225662B (en) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | Pharmaceutical compositions and dosage forms |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| AU2018392332B2 (en) | 2017-12-19 | 2023-08-03 | Turning Point Therapeutics, Inc. | Macrocyclic compounds for treating disease |
| AU2019218387A1 (en) | 2018-02-12 | 2020-08-27 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| WO2019168874A1 (en) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| EP3784675A1 (en) | 2018-04-23 | 2021-03-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| WO2019210835A1 (en) * | 2018-05-04 | 2019-11-07 | 正大天晴药业集团股份有限公司 | Diaryl macrocyclic compound as protein kinase modulator |
| CN108621206B (en) * | 2018-05-07 | 2020-08-14 | 昆山国显光电有限公司 | Glove box system and maintenance method for glove box system |
| CN112703001A (en) * | 2018-09-18 | 2021-04-23 | 株式会社益力多本社 | Combination cancer therapy using quinoline carboxamide derivatives |
| CN109081810A (en) * | 2018-09-20 | 2018-12-25 | 沈阳药科大学 | The synthetic method of 1- methyl-3-((methylamino) methyl)-1H- pyrazoles-5- nitrile |
| CN109232607A (en) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | Laura replaces the synthetic method of Buddhist nun |
| US12077528B2 (en) | 2018-11-28 | 2024-09-03 | Shenzhen Targetrx, Inc. | Preparation method for deuterated macrocyclic compound |
| KR20210107069A (en) | 2018-12-21 | 2021-08-31 | 다이이찌 산쿄 가부시키가이샤 | Combination of antibody-drug conjugates and kinase inhibitors |
| CN109651398B (en) * | 2019-01-25 | 2021-07-30 | 安庆多辉生物科技有限公司 | Bromide intermediate for synthesizing Laratinib and method for catalytically synthesizing Laratinib |
| CN109651397A (en) * | 2019-01-25 | 2019-04-19 | 安庆多辉生物科技有限公司 | A kind of Laura is for Buddhist nun's intermediate and prepares the method that Laura replaces Buddhist nun |
| CN109651418A (en) * | 2019-01-25 | 2019-04-19 | 安庆多辉生物科技有限公司 | A kind of method that Laura replaces Buddhist nun's bulk pharmaceutical chemicals synthetic intermediate and Organometallic Palladium catalytic coupling to prepare Laura for Buddhist nun |
| CN111499514B (en) * | 2019-01-31 | 2024-09-20 | 连云港润众制药有限公司 | Preparation method of roflumilast intermediate |
| US11976069B2 (en) | 2019-03-21 | 2024-05-07 | Merck Sharp & Dohme Llc | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection |
| CN112533927B (en) * | 2019-05-14 | 2025-06-17 | 苏州韬略生物科技股份有限公司 | Substituted macrocycles useful as kinase inhibitors |
| WO2021011345A1 (en) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (en) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | Macrocyclic JAK2 inhibitors and their applications |
| CN110483551B (en) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | Crystals of Laratinib free base |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112812128B (en) * | 2019-11-18 | 2024-04-02 | 正大天晴药业集团股份有限公司 | Macrocyclic compounds as ALK and ROS modulators |
| CN112824417A (en) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | Preparation method of Laolatinib |
| UY38979A (en) | 2019-12-06 | 2021-07-30 | Vertex Pharma | TETRAHYDROFURANS REPLACED AS SODIUM CHANNEL MODULATORS |
| CN111170908B (en) * | 2020-01-09 | 2021-08-17 | 北京印刷学院 | A kind of synthetic method of 2,4-dimethyl-3-methanesulfonyl halide benzene |
| US12539304B2 (en) | 2020-03-05 | 2026-02-03 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| KR102698413B1 (en) | 2020-05-05 | 2024-08-26 | 뉴베일런트, 아이엔씨. | Heteroaromatic macrocyclic ether chemotherapeutic agent |
| KR20240132391A (en) * | 2020-05-05 | 2024-09-03 | 뉴베일런트, 아이엔씨. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| US20230174554A1 (en) * | 2020-05-18 | 2023-06-08 | Shenzhen TargetRx. Inc. | Solid form of macrocyclic compound, preparation therefor and use thereof |
| EP4178958A4 (en) * | 2020-07-10 | 2024-12-11 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| MX2023007162A (en) * | 2020-12-17 | 2023-06-29 | Blossomhill Therapeutics Inc | Macrocycles and their use. |
| CN114805371B (en) * | 2021-01-19 | 2024-05-24 | 江苏开元药业有限公司 | Macrocyclic compound containing 2-aminopyrimidine and preparation method and application thereof |
| WO2022182845A1 (en) * | 2021-02-25 | 2022-09-01 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| WO2022214681A1 (en) | 2021-04-09 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
| CN115246843A (en) * | 2021-04-26 | 2022-10-28 | 苏州东南药业股份有限公司 | A Class of Fourteen-membered Condensed Ring Derivatives and Their Applications |
| TW202313593A (en) | 2021-06-04 | 2023-04-01 | 美商維泰克斯製藥公司 | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| TW202320768A (en) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds |
| EP4230201A1 (en) | 2022-02-21 | 2023-08-23 | Universidade Nova De Lisboa | Composition for treating neurodegenerative diseases |
| CA3244798A1 (en) | 2022-02-21 | 2023-08-24 | Universidade Nova De Lisboa | Compounds and compositions for neurodegenerative diseases |
| IL319638A (en) * | 2022-10-19 | 2025-05-01 | Nuvalent Inc | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| CN115746023B (en) * | 2022-10-27 | 2024-08-09 | 复旦大学 | Heterocyclic macrocyclic compound containing indazole structure as protein kinase inhibitor and preparation method thereof |
| CN118434744A (en) * | 2022-12-01 | 2024-08-02 | 中国医药研究开发中心有限公司 | Nitrogen-containing macrocyclic compound, and preparation method and medical application thereof |
| WO2024146541A1 (en) * | 2023-01-03 | 2024-07-11 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Macrocyclic compounds as usp1 inhibitors |
| CN120344244A (en) * | 2023-11-15 | 2025-07-18 | 深圳市塔吉瑞生物医药有限公司 | Methods for treating ALK-positive or ROS1-positive non-small cell lung cancer |
| WO2025212729A1 (en) * | 2024-04-03 | 2025-10-09 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and their use |
| WO2026008023A1 (en) * | 2024-07-04 | 2026-01-08 | 正大天晴药业集团股份有限公司 | Pyridazinamine compound and pharmaceutical use thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Cyclodextrin derivatives with increased water solubility and uses thereof |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| DE10239042A1 (en) | 2002-08-21 | 2004-03-04 | Schering Ag | New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
| CN103265477B (en) | 2003-02-26 | 2017-01-11 | 苏根公司 | Aminoheteroaryl compounds as protein kinase inhibitors |
| WO2004078682A2 (en) | 2003-03-05 | 2004-09-16 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| JO2785B1 (en) * | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
| WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
| BRPI0514458A (en) | 2004-08-25 | 2008-06-10 | Pfizer | triazolbenzodiazepines and their use as vasopressin antagonists |
| PL1786785T3 (en) * | 2004-08-26 | 2010-08-31 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinases |
| SI1784396T1 (en) | 2004-08-26 | 2011-03-31 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
| KR101026676B1 (en) | 2005-12-05 | 2011-04-04 | 화이자 프로덕츠 인코포레이티드 | How to treat abnormal cell growth |
| EP1963302B1 (en) | 2005-12-05 | 2013-02-27 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
| WO2008088881A1 (en) | 2007-01-19 | 2008-07-24 | Xcovery, Inc. | Kinase inhibitor compounds |
| CN101675059A (en) | 2007-03-01 | 2010-03-17 | 中外制药株式会社 | Macrocyclic compounds |
| EA200901059A1 (en) * | 2007-03-13 | 2010-02-26 | Пфайзер Продактс Инк. | Macrolides on the basis of erythromycin |
| WO2009099982A1 (en) * | 2008-02-04 | 2009-08-13 | Osi Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| CA2722326A1 (en) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| WO2009146802A1 (en) * | 2008-06-06 | 2009-12-10 | Sanofi-Aventis | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia |
| EA201100450A1 (en) * | 2008-09-08 | 2011-10-31 | Мерк Патент Гмбх | MACROCYCLIC PYRAMIDINES AS PROTEINKINASE INHIBITORS |
| WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| US20120258993A1 (en) | 2009-10-21 | 2012-10-11 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents |
| US8383793B2 (en) * | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| WO2011138751A2 (en) * | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| SMT201900203T1 (en) * | 2010-05-20 | 2019-05-10 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| US8975232B2 (en) | 2010-07-29 | 2015-03-10 | President And Fellows Of Harvard College | Macrocyclic kinase inhibitors and uses thereof |
| EP2686323A1 (en) | 2011-03-16 | 2014-01-22 | Cephalon, Inc. | Macrocyclic compounds as alk, fak and jak2 inhibitors |
-
2013
- 2013-02-20 CA CA2863892A patent/CA2863892C/en active Active
- 2013-02-20 ES ES13717555.0T patent/ES2621220T3/en active Active
- 2013-02-20 HR HRP20170287TT patent/HRP20170287T2/en unknown
- 2013-02-20 WO PCT/IB2013/051391 patent/WO2013132376A1/en not_active Ceased
- 2013-02-20 MX MX2014010716A patent/MX350844B/en active IP Right Grant
- 2013-02-20 KR KR1020147027905A patent/KR101692600B1/en active Active
- 2013-02-20 RS RS20170280A patent/RS55814B1/en unknown
- 2013-02-20 PE PE2014001329A patent/PE20142339A1/en active IP Right Grant
- 2013-02-20 ME MEP-2017-42A patent/ME02630B/en unknown
- 2013-02-20 LT LTEP13717555.0T patent/LT2822953T/en unknown
- 2013-02-20 HU HUE13717555A patent/HUE034118T2/en unknown
- 2013-02-20 MY MYPI2014702342A patent/MY169142A/en unknown
- 2013-02-20 SI SI201330542A patent/SI2822953T1/en unknown
- 2013-02-20 PT PT137175550T patent/PT2822953T/en unknown
- 2013-02-20 PL PL13717555T patent/PL2822953T3/en unknown
- 2013-02-20 GE GEAP201313564A patent/GEP201606560B/en unknown
- 2013-02-20 NZ NZ627900A patent/NZ627900A/en unknown
- 2013-02-20 SG SG11201404451TA patent/SG11201404451TA/en unknown
- 2013-02-20 JP JP2014560470A patent/JP5823066B2/en active Active
- 2013-02-20 EA EA201491394A patent/EA026155B9/en active Protection Beyond IP Right Term
- 2013-02-20 AU AU2013229173A patent/AU2013229173B2/en active Active
- 2013-02-20 CN CN201380012703.XA patent/CN104169286B/en active Active
- 2013-02-20 DK DK13717555.0T patent/DK2822953T5/en active
- 2013-02-20 EP EP13717555.0A patent/EP2822953B9/en active Active
- 2013-02-20 AP AP2014007881A patent/AP2014007881A0/en unknown
- 2013-02-20 BR BR112014022106-5A patent/BR112014022106B1/en active IP Right Grant
- 2013-02-20 MD MDA20140086A patent/MD4590C1/en active IP Right Grant
- 2013-03-04 AR ARP130100694 patent/AR090230A1/en active IP Right Grant
- 2013-03-04 TW TW102107486A patent/TWI476199B/en active
- 2013-03-05 US US13/786,106 patent/US8680111B2/en active Active
- 2013-03-06 UY UY34657A patent/UY34657A/en active IP Right Grant
-
2014
- 2014-01-15 US US14/156,144 patent/US9133215B2/en active Active
- 2014-08-01 CR CR20140370A patent/CR20140370A/en unknown
- 2014-08-06 CL CL2014002084A patent/CL2014002084A1/en unknown
- 2014-08-11 IL IL234062A patent/IL234062A/en active IP Right Grant
- 2014-08-18 DO DO2014000188A patent/DOP2014000188A/en unknown
- 2014-08-25 ZA ZA2014/06244A patent/ZA201406244B/en unknown
- 2014-09-05 NI NI201400102A patent/NI201400102A/en unknown
- 2014-09-05 PH PH12014501992A patent/PH12014501992A1/en unknown
- 2014-09-05 GT GT201400187A patent/GT201400187A/en unknown
- 2014-09-08 CO CO14198153A patent/CO7061081A2/en unknown
-
2015
- 2015-10-05 JP JP2015197955A patent/JP6002825B2/en active Active
-
2017
- 2017-03-27 CY CY20171100376T patent/CY1118771T1/en unknown
-
2019
- 2019-08-02 CY CY2019033C patent/CY2019033I1/en unknown
- 2019-08-19 NO NO2019034C patent/NO2019034I1/en unknown
- 2019-09-12 HU HUS1900040C patent/HUS1900040I1/en unknown
- 2019-09-17 NL NL301006C patent/NL301006I2/en unknown
- 2019-10-01 LU LU00131C patent/LUC00131I2/fr unknown
- 2019-10-18 LT LTPA2019519C patent/LTC2822953I2/en unknown
- 2019-10-23 FR FR19C1062C patent/FR19C1062I2/en active Active